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The structure of a complex of human 17b-hydroxysteroid
dehydrogenase with estradiol and NADP+ identifies two 
principal targets for the design of inhibitors
Rock Breton†, Dominique Housset, Catherine Mazza and Juan Carlos
Fontecilla-Camps*
Background: The steroid hormone 17b-estradiol is important in the genesis and
development of human breast cancer. Its intracellular concentration is regulated
by 17b-hydroxysteroid dehydrogenase, which catalyzes the reversible reduction
of estrone to 17b-estradiol. This enzyme is thus an important target for inhibitor
design. The precise localization and orientation of the substrate and cofactor in
the active site is of paramount importance for the design of such inhibitors, and
for an understanding of the catalytic mechanism.
Results: The structure of recombinant human 17b-hydroxysteroid
dehydrogenase of type 1 (17b-HSD1) in complex with estradiol at room
temperature has been determined at 1.7 Å resolution, and a ternary 17b-
HSD1–estradiol–NADP+ complex at –150°C has been solved and refined at
2.20 Å resolution. The structures show that estradiol interacts with the enzyme
through three hydrogen bonds (involving side chains of Ser142, Tyr155 and
His221), and hydrophobic interactions between the core of the steroid and nine
other residues. The NADP+ molecule binds in an extended conformation, with
the nicotinamide ring close to the estradiol molecule.
Conclusions: From the structure of the complex of the enzyme with the substrate
and cofactor of the oxidation reaction, the orientation of the substrates for the
reduction reaction can be deduced with confidence. A triangular hydrogen-bond
network between Tyr155, Ser142 and O17 from estradiol probably facilitates the
deprotonation of the reactive tyrosine, while the conserved Lys159 appears not to
be directly involved in catalysis. Both the steroid-binding site and the NADPH-
binding site can be proposed as targets for the design of inhibitors.
Introduction
It is well known that 17b-estradiol (E2), plays an important
role in the genesis and development of human breast
cancer [1,2]. 17b-Hydroxysteroid dehydrogenase (17b-
HSD) mediates the reversible interconvertion of the bio-
logically inactive estrogen, estrone (E1), to the most active
estrogen E2, and thus plays a crucial role in the regulation
of intracellular levels of active estrogens in a variety of
tissues, including normal and cancerous mammary gland
[3–5]. In the endometrium and in hormone-independent
human breast cancer cell lines, 17b-HSD activity favours
the formation of E1 [6,7]. In contrast, in hormone-depen-
dant cell lines the reductive activity of 17b-HSD, leading
to the formation of the most potent estrogen E2 from E1,
is predominant [8–11].
The 17b-HSD reaction is catalyzed by five isozymes desig-
nated 17b-HSD types 1 to 5 [12,13]. The 17b-HSD type 1
enzyme (17b-HSD1), also referred to as estradiol 17b-dehy-
drogenase, is a cytosolic protein that almost exclusively cat-
alyzes the reductive reaction (E1→E2) when transiently
expressed in cultured mammalian cells [13,14]. A dinu-
cleotide cofactor, either NADPH or NADH, is required for
the reaction. Because of its key role in the biosynthesis of
active estrogen, this enzyme represents an important target
for cancer therapy. A better knowledge of its three-dimen-
sional structure, and especially of those regions involved in
specific recognition and binding of steroid substrate, should
be instrumental in the design of novel therapeutic agents
for the inhibition of estrogen production in the endocrine
therapy of breast and other estrogen-sensitive cancers [15].
Primary structure alignments, affinity-labelling studies and
site-directed mutagenesis experiments have been used to
characterize 17b-HSD1 and to predict the amino acid com-
position and structure of its active site. The enzyme (MW
34900, 327 residues) belongs to the short-chain alcohol
dehydrogenase (SCAD) superfamily [16–18] which can
show up to six significantly conserved domains (A–F) iden-
tified by multiple sequence alignment. The D domain
contains the characteristic Tyr-X-X-X-Lys sequence
(Tyr155 and Lys159 in 17b-HSD1) which is conserved in
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almost all members of the SCAD superfamily and found to
be essential for enzymatic activity [19,20]. The enzyme is
active as an homodimer [21]. Several studies have been
carried out in order to determine precisely which residues
are part of the active site. Chemical modification of specific
amino acids suggested that the conserved tyrosine residue
may be involved in dimerization of subunits in glucose
dehydrogenase [22,23]. However, crystallographic analysis
of bacterial 3a,20b-hydroxysteroid dehydrogenase (3a,20b-
HSD) and modelling studies with cortisone in the catalytic
site [24,25] reveal that the Tyr-X-X-X-Lys sequence along
with Ser139 are located in the active site. These residues
may promote electrophilic attack of the (C20–O) carbonyl
oxygen atom from the cortisone molecule, thus enabling
the carbon atom to accept a hydride radical from the
reduced cofactor [26]. Site-directed mutagenesis experi-
ments have confirmed the importance of Tyr155 for the
activity of human 17b-HSD1 but the lowered catalytic effi-
ciency of the mutant enzyme may also be due to significant
changes in its three-dimensional structure, as suggested by
the reduced immunoreactivity of the mutant enzyme [27].
Three histidine residues (His210, His213 and His221) of
human 17b-HSD1, identified by affinity-labelling studies
[28,29] and not conserved in other members of the SCAD
superfamily, were also believed to be located near the
steroid-binding site and to be involved in hydrogen trans-
fer. However, as recently demonstrated by site-directed
mutagenesis experiments, only His221 seems to play a role
in steroid binding [27] (CM, unpublished results). This
residue is thought to play a structural role as its substitu-
tion by either alanine or leucine causes a reduction of
immunoreactivity [27] as well as a change in the crystal’s
symmetry (CM, unpublished results).
Because the precise localization and orientation of the
steroid in the active site is of paramount importance for
the design of effective and specific inhibitors of human
17b-HSD1, we have co-crystallised the enzyme with its
17b-estradiol substrate and NADP+ and determined the
structure of this complex both at room temperature and at
low temperature (-150°C). Recombinant 17b-HSD1, over-
produced with a baculovirus expression system and puri-
fied from Spodoptera frugiperda (Sf9) insect cells [30], was
used as a source of enzyme.
Recently, the three-dimensional structure of human 17b-
HSD1 has been determined independently at 2.20 Å reso-
lution [31]. No density corresponding to the cofactor and
the steroid was found although 1mM NADP+ was present
in the crystallization medium. The positions of 17b-estra-
diol and the NADP+ cofactor were subsequently modelled,
the latter being derived from a superposition of the struc-
tures of 17b-HSD1 and the 3a,20b-HSD–NAD+ complex
[25]. From these modelling studies, a model for the estrone
to estradiol transition state has been proposed. It is clear,
however, that only the structure of the ternary complex
will furnish a detailed enzyme–substrate interaction at the
active site and a putative mechanism description.
This report describes the structures of the 17b-HSD1–
estradiol binary complex at 1.7 Å resolution and of the
17b-HSD1–estradiol–NADP+ ternary complex at 2.20 Å
resolution. A detailed analysis of the interactions between
the enzyme and its substrate and cofactor is presented.
Based on our results, a realistic scheme for the catalytic
mechanism can be proposed for the reduction reaction.
Results
Overall description of the protein structure
The protein structure does not seem to show any major
differences from the model previously published [31].
However, a detailed comparison is not possible as the coor-
dinates for this model are not currently available. As deter-
mined by the program DSSP [32], 17b-HSD1 contains
seven b strands forming a parallel b sheet and 11 a helices
(Table 1). The structure is of the α/b type, including the
so-called ‘Rossman fold’, often encountered in dinu-
cleotide-binding domains (Fig. 1). Moreover, the structure
includes two helix-turn-helix motifs (aG′′–aG′ and
aH′–aH), the latter being involved in dimer formation. No
electron density was present for the C-terminal end of the
polypeptide chain (residues 288–327), and consequently
no model has been built for it. However, mass spec-
troscopy experiments performed on one of our dissolved
crystals showed that all the residues were present (MW
34889±1.5, E Forest, unpublished result). Thus, this part
of the chain, which is rich in glycine and alanine residues
(19 out of 43), seems to be disordered in the crystal. The
packing interactions are very similar to those described by
Ghosh et al. [31] for the protein alone. Neither the cofactor
nor the substrate is involved in interactions with symme-
try-related molecules. The main characteristic of the
packing is the formation of a crystallographic dimer,
thought to be equivalent to the active dimer in solution.
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Table 1
Secondary structure elements of 17b-HSD1, as determined by
DSSP. 
a Helices Residue range b Strands Residue range
bA 3–7
aB 13–23 bB 30–36
aC 43–51 bC 59–63
aD 69–77 bD 86–89
aE¢ 104–114
aE 116–132 bE 135–142
aF 153–173 bF 178–185
aG′′ 200–206
aG′ 209–229
aG 233–245 bG 252–254
aH′ 260–268
aH 273–283
Bold characters indicate the Rossman fold topology.
Room temperature model at 1.7 Å resolution
The final room temperature model includes residues
1–285, one estradiol molecule and 127 water molecules.
The electron density for estradiol was clearly visible in
difference Fourier maps during model building. The
structure of estradiol dihydrate, retrieved from the Cam-
bridge database [33], was fitted to the (Fo–Fc) electron-
density map and then refined with the rest of the model.
The electron-density map is very well defined except for
residues 192–198 and the C-terminal end (residues
289–327) which appear to be disordered and were not
included in the model. Moreover, five residues (Leu45,
Arg67, Arg132, Phe226 and Leu241) were each built with
two conformations. The (2Fo–Fc) electron-density map
corresponding to the steroid is of good quality (Fig. 2).
However, its average B factor is significantly higher than
for the rest of the model, indicating that the steroid, even
if buried in a hydrophobic pocket and stabilized through
hydrogen bonds involving hydroxyl groups O3 and O17,
could be quite mobile in the crystal structure and the
steroid-binding site may not be fully occupied. In addi-
tion, the hydroxyl group O17 is located in the proximity of
the disordered region (residues 192–198) and points
towards a pocket corresponding to the NADP+-binding
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Figure 1
The overall structure of 17b-
HSD1–estradiol–NADP+ complex. (a)
Stereoscopic view of 17b-HSD1, complexed
with estradiol and NADP+. Red arrows
represent b strands, a helices are depicted in
purple and the rest of the backbone is
represented as a yellow coil. Residues
190–197, corresponding to the disordered
region, are shown in magenta. The estradiol
and NADP+ molecules are depicted as
orange and turquoise ball-and-stick models,
respectively. (Figure generated with Molscript
[51] and Render [52,53]). (b) Stereoscopic
view of the Ca backbone, in the same
orientation as (a). The substrate and cofactor
are shown in grey. Residues implicated in the
catalytic mechanism (Ser142, Tyr155 and
Lys159) are depicted as circles.
site. Phe226, modelled with two conformations also points
to this region.
Steroid-binding site
The estradiol molecule is located in a pocket formed at
the interface of the aG′ helix and the loop between bE
and aF. The steroid moiety is mainly stabilized by three
hydrogen bonds at its ends: between O3 and Ne2 of
His221 (3.14 Å); between O17 and Og of Ser142 (3.20 Å);
and between O17 and Oh of Tyr155 (3.37 Å). The core of
the steroid is maintained with several hydrophobic inter-
actions involving Val143, Met147, Leu149, Pro187,
Tyr218, Val225, Phe226, Phe259 and Met279 (Fig. 3). A
potential hydrogen bond may occur between the hydroxyl
groups of Ser142 and Tyr155 (3.49 Å), forming a triangle-
shaped hydrogen-bond network with the O17 hydroxyl
group. Moreover, the NH of Gly144 points towards Ser142
Og, forming a tight hydrogen bond. Thus, the Ser142
hydroxyl group could serve as a hydrogen donor either to
estradiol O17 or to the Tyr155 hydroxyl group.
Low temperature model at 2.2 Å resolution
No major differences were found in the overall protein
structure, when the low temperature and room temperature
models were compared. The root mean square (rms) differ-
ence, calculated for 274 Ca atoms is 0.24 Å. However, for
the low temperature model additional electron density was
detected in the NADP+ binding region, close to the active
site (Fig. 4). Subsequently, it was possible to model the
complete dinucleotide. In order to obtain comparable B
factors for the residues of the binding pocket (17.6 Å2) and
for NADP+ (28.3 Å2), the occupancy of NADP+ had to be
set to 0.5. As B factors and occupancies are highly correlated
parameters, it is impossible to refine them independently.
Thus, this occupancy value is somehow arbitrary, but seems
more plausible than assuming large positional fluctuations.
This means that, in the crystal, the dinucleotide-binding
site may be occupied only half of the time. The nicoti-
namide ring, and the three phosphate groups have unam-
biguous matching electron density, while ribose groups are
built into less well-defined electron density. The adenine
group, exposed to the solvent, could be placed in some rea-
sonable electron density, shared with an alternate confor-
mation of the Arg37 side chain. Moreover, some of the
residues of the disordered loop (residues 192–198) in the
room temperature model could now be built into the elec-
tron density. Residues 192–195 still lack matching electron
density, but two plausible conformations have been built
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Figure 2
Stereoscopic view of the electron density
around the steroid molecule. The 2Fo–Fc map,
computed with 1.7 Å resolution data, is
contoured at the 1s level.
for this part of the polypeptide chain. It appears that the
loop may adopt a specific conformation when the NADP+
binds to the enzyme, and may stabilize the nicotinamide
ribose group. This phenomenon has already been observed
for other NADP+–enzyme complexes [34]. The average 
B factor is significantly lower for the low temperature struc-
ture (Table 2), indicating a reduced mobility of the mol-
ecule, particularly in the active site region. Even if the
NADP+-binding site may not be fully occupied by the din-
ucleotide, there is no ambiguity for the interpretation of the
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Figure 3
Stereoscopic view of the residues of 17b-
HSD1 (light grey) interacting with the
estradiol molecule (dark grey). Phe226 is
shown with its two modelled conformations.
Figure 4
Stereoscopic view of the residual electron-
density map around NADP+. The omit Fo–Fc
map is computed at 2.2 Å resolution and
contoured at the 2.8s level. The dinucleotide
molecule was excluded for the computation of
calculated structure factors and phases.
electron density and the relative positions of the three com-
ponents of the complex are now clearly defined.
NADP+-binding site
The NADP+ molecule binds in an extended conforma-
tion, with the nicotinamide moiety pointing towards the
active site of the enzyme (Fig. 5). The nicotinamide ring
is in a syn conformation while the adenine ring is in an anti
conformation. The B side of the nicotinamide faces the D
ring of the steroid, thus allowing the pro-S hydride to be
transferred to the latter. The two ribose moieties are C2′-
endo puckered, consistent with other short-chain dehy-
drogenase structures such as dihydropteridine reductase
(DHPR) [35,36]. The nicotinamide ring faces the D ring
of the steroid, the distance between the nicotinamide C4
atom (hydride donor) and estradiol C17 being 3.62 Å. The
major interactions with the protein involve hydrogen
bonds with 11 residues (C10, S11, S12, I14, G15, R37,
D65, N90, G92, T140, K159, V188 and T190) and
hydrophobic contacts with two additional residues (Gly9
and Ala91). In addition, three buried water molecules are
hydrogen bonded to the dinucleotide (Fig. 6). The amide
nitrogen of Val188 forms a hydrogen bond with the nicoti-
namide’s amide group. The nicotinamide ribose is mainly
stabilized through two hydrogen bonds between O2′ and
O3′ and the Lys159 Nz atom, and one hydrogen bond
between Thr140 Og1 and O5′. The two central phosphate
groups hydrogen bond to the main chain NH groups of
Ile14 and Gly15 and to Nd1 of Asn90. The phosphate
bound to the adenine ribose is stabilized through three
hydrogen bonds formed with the backbone amide groups
of Cys10, Ser11 and Arg37, while the ribose itself forms
two hydrogen bonds: one between O5′ and Gly92 NH and
one between O3′ and the hydroxyl group of Ser11. The
adenine, which is fairly exposed to the solvent, only inter-
acts with the side chain of Asp90.
Discussion
To our knowledge, this structure constitutes the second
published protein–steroid complex three-dimensional X-
ray model. The structure shows that the steroid binds
through both hydrophobic interactions, concerning the core
of the steroid, and three hydrogen bonds at its ends
(Fig. 3). The hydrophobic residues essentially protect the
four steroid rings from solvent, but do not interact very
tightly with the estradiol core. Consequently, the steroid
may be able to move slightly in its pocket, as illustrated by
its slightly higher B factor values. The hydrogen bonds
between O17, and the highly conserved Ser142 and Tyr155
putative catalytic residues (Fig. 6), should be a common
feature of 17b-HSD–steroid interactions. On the other
hand, the hydrogen bond between O3 and His221 seems to
be more specific of steroids with a hydroxyl or a carbonyl
group on C3, such as estradiol (a substrate of 17b-HSD1
and 17b-HSD2) or androstenedione (a substrate of 17b-
HSD2 and 17b-HSD3). However, the sequence alignment
of three 17b-HSD’s (types 1 to 3) cannot unambiguously
determine the type of residue structurally equivalent to
His221 in 17b-HSD1. Puranen et al. [27] have shown that
the catalytic efficiency of the His221→Ala mutant of 17b-
HSD1 was ten to twenty times lower than that of the wild
type. Thus, this residue could be a good target to monitor
the steroid affinity. Furthermore, a pathway allowing the
steroid to enter the binding site is formed by His221,
Leu262 and Pro263.
Our structure also sheds light on the catalytic mechanism
for the reduction of estrone to estradiol, as the spatial orga-
nization of all participants is now completely defined.
Consequently, a tentative description of the reaction can
be formulated (Fig. 7). A tentative mechanism, based on a
sequence alignment and molecular modelling, had previ-
ously been proposed concerning the reduction of estrone
to estradiol [31]. The present work shows that although
some of the elements of this earlier mechanism are basi-
cally correct, it is now possible to define the exact role of
the implicated residues. The mechanism proposed here is
very similar to the one suggested recently for mouse lung
carbonyl reductase (MLCR) [37], despite some slight dif-
ferences in the catalytic serine and tyrosine side chain ori-
entation. The reduction reaction involves a proton and an
hydride which are transferred to the estrone molecule.
Both Ser142 and Tyr155 could donate a proton to O17.
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Table 2
Refinement statistics.
Model at 20°C Model at –150°C
Model
Number of residues 285 285
Number of atoms
protein 2181 2256
estradiol 20 20
NADP+ 0 48
solvent 127 142
Data F >2s(F) 
Resolution (Å) 10.0–1.70 10.0–2.20
Number of reflections 31 798 13 396
Completeness (%) 88.3 84.8
R factor 0.178 0.193
Free R factor 0.203 0.243
Stereochemistry
Stereochemistry standard 
deviation from ideality
bonds (Å) 0.011 0.013
angles (°) 1.72 2.02
improper angles (°) 1.33 1.63
Average B factor (Å2)
main chain 22.5 17.8
side chain 25.8 19.3
estradiol 54.8 48.2
NADP+ – 28.3*
solvent 36.7 29.1
*Occupancy set to 0.5 (see text).
However, due to its lower pKa, the tyrosine residue seems
to be the best candidate. Thus, Ser142 should be able to
share its proton with Tyr155, stabilizing the unprotonated
state of the tyrosine residue. If Tyr155 is the proton donor,
the serine’s role may be to lower the apparent pKa (pKaap)
of the tyrosine. Located on the other side of the steroid,
the nicotinamide liberates the pro-S hydride, 3.62 Å away
from C17 (Fig. 5). The optimum pH for the reduction
reaction is close to six while the optimum pH for oxidation
is between 8 and 10. As the pKa of tyrosine in water is
close to 10.1, the whole environment around Tyr155
should be designed to help its deprotonation. The proxim-
ity of hydrophobic residues (possibly including Phe192
from the disordered loop), which shield the active site
from the solvent, would certainly reduce the pKaap. The
exact role of Lys159 also needs to be clarified. Ghosh et al.
[31] proposed that the side chain of Lys159 could easily
move and form a putative hydrogen bond with the
hydroxyl group of the tyrosine. Despite the inherent flexi-
bility of this type of residue, no evidence for an enhanced
mobility of Lys159 is supported by our crystal structure;
the position of this buried side chain is very well defined
in electron density and is structurally conserved among
other proteins of the SCAD family for which the structures
are known (3a,20b-HSD and DHPR). Furthermore, the
relative positions of Tyr155 and Lys159, separated by 4.3
Å (distance between the tyrosine hydroxyl group and the
lysine Nz atom), seem to be a constant feature for these
enzymes. Thus, the major role of Lys159 could be the sta-
bilization of the dinucleotide through the interaction with
the nicotinamide ribose, as for Lys156 in MLCR [37].
Moreover, the presence of five buried water molecules in
the neighbourhood of the lysine residue that connect the
active site with the protein surface, support the idea that
Lys159 is involved in a proton transfer chain.
Although there is now a clear description of the active site,
and of the background for the enzymatic reaction, it is not
clear which factors could favour the reduction or the oxi-
dation process. 17b-HSD1 is able to catalyze both reac-
tions depending on the pH, while 17b-HSD2 essentially
catalyzes the oxidation reaction only [13]. Thus, a
sequence alignment of 17b-HSD1 and 17b-HSD2 could
shed light on the residues implicated in this reaction.
Unfortunately, due to the low level of sequence identity
(~23%), an accurate alignment is not available for some
regions of the enzyme, including the disordered loop
(residues 191–198) and the a helix G′. Thus the role of
some residues close to the active site cannot be elucidated
at this time. For 17b-HSD1, we can estimate the Tyr155
pKaap to fall between six and nine. For both reactions the
optimal pH should not be too far from the pKaap, in order
to make protonation or deprotonation possible. The tyro-
sine should be protonated for the reduction reaction
(pH≤pKaap), and able to accept a proton for the oxidation
reaction (pH≥pKaap).
The structures we have determined also shed some light
on the cofactor specificity. It seems that 17b-HSDs, which
preferentially catalyse the reduction of their substrates,
have higher affinity for NADP+ than for NAD+ [13,38],
but this point has been much debated. 17b-HSD1 lacks
the two proximal basic residues which stabilize the 2′-
ribose phosphate in NADPH-preferring enzymes. In view
of this, and assuming that Leu36 could share the position
of the conserved proximal aspartic acid in NADH-prefer-
ring enzymes, Tanaka et al. [37] proposed that 17b-HSD1
should still be classified as an NADH-preferring enzyme.
However, in the structure of 17b-HSD1, the side chain of
Leu36 points towards the inside of the enzyme, and is
located in an hydrophobic environment made of residues
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Figure 5
Stereoscopic close-up view of the active site.
Protein residues are show in light grey,
estradiol and NADP+ in dark grey. Dashed
lines represent hydrogen bonds between
estradiol and residues Ser142, Tyr155 and
His221. The dotted line illustrates the hydride
pathway from the nicotinamide N5 atom to the
estradiol C17 atom.
Cys11 (Ca), Gln42 (Ca), Leu42 (side chain) and Thr61
(Cb, Cg2). This is in contrast to the situation in 3a,20b-
HSD where the side chain of Asp37 points towards adeno-
sine ribose. Consequently, in 17b-HSD1 the 2′-phosphate
is able to approach its binding pocket in which it is mainly
stabilized through hydrogen bonds with main chain NH
groups of residues Cys10, Ser11 and Arg37. Recently,
Luu-The et al. [13] have shown that 17b-HSD1 and 17b-
HSD3, which catalyze the reduction reaction in vivo are
NADPH-preferring enzymes, while 17b-HSD2, which
catalyzes the oxidation reaction is an NAD+-preferring
enzyme. This result is consistent with the sequence align-
ment of these three enzymes; in 17b-HSD1 and 17b-
HSD3 Leu36 is conserved, while 17b-HSD2 has a
glutamic acid residue at this position. Mutation experi-
ments on Drosophila alcohol dehydrogenase, whose proxi-
mal aspartic acid was changed to an asparagine residue,
showed a 62-fold increase in NADP+ affinity [39]. Thus, a
negatively charged residue like aspartic acid or glutamic
acid seems to prevent NADPH binding, whereas a polar
or hydrophobic residue at this position allows for it. 
On the basis of the structures presented here, two princi-
pal targets can be proposed for the design of inhibitors:
the steroid-binding site and the dinucleotide-binding site.
The binding of an inhibitor in the hydrophobic pocket or
to residue His221 would most certainly prevent steroid
binding, or at least alter the substrate specificity. Fixing 
an inhibitor to Ser12 or Lys159 would certainly prevent
NADPH binding.
It also appears that the simultaneous modification of
Ser142 and Tyr155 abolishes all enzymatic activity. It is
not clear, however, whether the modification of just one of
them may be enough to keep some residual activity.
Neither His221 nor Tyr155 seem to be essential to pre-
serve the overall structure of the enzyme. Puranen et al.
[27] have shown that the mutation of either of these
residues to alanine leads to the loss of immunoreactivity, as
determined by native polyacrylamide gel electrophoresis
(PAGE). As these residues are accessible to the solvent,
the loss of immunoreactivity could be due to their direct
interaction with the antibody. However, the drastic change
in side chain volume due to the mutation may cause minor
structural modifications in the neighbourhood of these
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Figure 7
Scheme of the proposed reduction mechanism of estrone to estradiol.
Hydrogen bonds are represented with dashed lines. The reaction
implies the electrophilic attack of the Tyr155 Oh proton on estradiol
O17, and the nucleophilic attack of the nicotinamide pro-S hydride on
estradiol C17. Buried water molecules and Lys159 would participate
in a proton transfer chain, in order to reprotonate Tyr155.
Figure 6
Scheme of interactions between NADP+ and 17b-HSD1, at –150°C.
Dashed lines represent hydrogen bonds.
residues, thus preventing the binding of the antibody. The
structure of the ternary complex does not provide any
useful clues to establish whether dimerization is necessary
for enzymatic activity. The fact that the dimer is formed
through an exact crystallographic twofold axis in this space
group may abolish some slight differences between the
monomers that would enable their cooperativity in solu-
tion. Moreover, the exact role and structure of the two dis-
ordered regions (residues 192–198 and 286–327) have still
to be determined.
Biological implications
17b-estradiol is known to be a potent stimulator of human
breast cancer. The biosynthesis of this active steroid is
catalyzed by the enzyme 17b-hydroxysteroid dehydroge-
nase (17b-HSD), which reduces estrone to estradiol. This
protein belongs to the short-chain dehydrogenase family
of proteins, which share a common fold (termed the
Rossman or dinucleotide-binding fold) and an invariant
sequence Tyr-X-X-X-Lys, known to be essential for the
enzymatic reaction. The structure of several members of
this family of enzymes have been recently determined
(dihydropterine reductase, 3a,20b-HSD, 17b-HSD1),
sheding light on the locations of the catalytic and dinu-
cleotide-binding sites. However, a clear picture of sub-
strate and cofactor binding to 17b-HSD1, a necessary
step for the design of potential inhibitors and therapeutic
agents, was not yet available.
This study presents the high-resolution structure of the
ternary complex between the enzyme, the substrate
(estradiol) and the cofactor (NADP+). On the basis of
this structure, we have been able to precisely describe the
steroid- and dinucleotide-binding sites. The nature of the
residues implicated in the catalytic reaction (Ser142 and
Tyr155), and of those stabilizing the cofactor and the sub-
strate, together with the role of the conserved Lys159 in
stabilizing a ribose group of NADP+, are now clearly
established. A catalytic mechanism is proposed for the
reduction of estrone to estradiol, involving a triangle-
shaped hydrogen-bond network between the hydroxyl
group of Ser142 and Tyr155, and the steroid O17 atom.
The presence of a leucine residue at position 36 (instead
of an aspartic acid residue, as is usually encountered for
NADH-preferring enzymes) explains the higher affinity
of the enzyme for NADPH. This information should be
of paramount importance in aiding the design of mol-
ecules of therapeutic value that could prevent either sub-
strate or cofactor binding, thus blocking estradiol
synthesis.
Materials and methods
Purification of recombinant 17b-HSD
Recombinant 17b-HSD overproduced in a baculovirus expression
system was purified with a modification of a previously described proce-
dure [30]. Briefly, infected Sf9 cells were sonicated on ice and unbroken
cells and nuclei were pelleted by centrifugation (90 min at 31400 g).
The clear supernatant was diluted approximately two times with a buffer
solution containing 40mM Tris-HCl pH 7.5, 1 mM EDTA, 0.2 mM DTT,
and 20% (v/v) glycerol (17b-buffer). The latter was directly loaded on to
a Blue-Sepharose CL-6B affinity column, and washed with 80mM NaCl,
before stepwise elution with NADP+. Recombinant 17b-HSD1 eluted at
about 20 mM NADP+ and resulted in a homogenous preparation.
Crystallization of recombinant 17b-HSD1 in the presence of
17b-estradiol 
Crystallization of recombinant 17b-HSD1 was carried out as described
for the human placental enzyme [40]. Briefly, the recombinant enzyme
concentrated at 10 mg ml–1 in the presence of 2 mM b-octylglucoside
and 20% glycerol was crystallized in a buffer containing 100 mM
HEPES pH 7.5, 100 mM MgCl2 and 24–26% PEG 4000 as precipi-
tant. Under these conditions, 17b-estradiol has very limited solubility
(between 25–50 µM) while the 17b-HSD1 concentration used in crys-
tallization (10 mg ml–1) corresponds to a concentration of about 150
mM for the protein dimer (capable of binding 300 mM of 17b-estra-
diol). In order to obtain the 17b-HSD1–estradiol complex, we slightly
changed the crystallization conditions by decreasing the enzyme con-
centration (from 10 mg ml–1 to 4.5 mg ml–1) and increasing the PEG
4000 concentration (from 24 to 32%). At 32% PEG, 500 µM of 17b-
estradiol could easily be dissolved corresponding to more than three
molecules of steroid per enzyme-binding site. Under these conditions,
monoclinic crystals appeared after ten days at room temperature and
continued to grow during seven to ten days.
Crystals used for cryocrystallographic experiments were incubated for
a few minutes in the same buffer to which 30% (v/v) glycerol was
added before the crystals were flashed-cooled under a nitrogen gas
stream at –150°C.
Crystals of recombinant 17b-HSD1 were soaked in several heavy-atom
containing solutions. Three of these heavy atom reagents gave a small
number of significant peaks in the difference Patterson maps. The
reagents and soaking conditions are summarized in Table 3.
Data collection and processing
Several native data sets where collected at different temperatures and
with different X-ray sources. One data set was collected at room tem-
perature at the W32 synchrotron beam line at LURE (Orsay, France).
These data were recorded on an 18 cm diameter Mar Research image
plate and processed with MOSFLM (version 5.20) [41] and CCP4
(version 2.12) [42]. Two data sets were collected at low temperature
(–150°C). One on the laboratory’s Siemens/Xentronics area detector
X1000 system, mounted on a Rigaku RU200 rotating-anode X-ray gen-
erator, and another one at the D2AM French-CRG synchrotron beam
line at the ESRF, using a XRII-CCD detector [43]. Data were
processed with XENGEN [44] for the former, and with a modified
version of XDS [45,46] for the latter. The data collection statistics are
summarized in Table 4. The 17b-HSD1 crystals belong to the mono-
clinic space group C2. Cell dimensions of room temperature and flash-
cooled crystals differ slightly: a=122.33 Å b=44.84 Å c=60.96 Å
b=98.84°; and a=122.765 Å b=43.786 Å c=60.528 Å b=99.468°,
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Table 3
Soaking solutions of heavy-atom derivatives.
Solution number Compound Concentration Soaking time
(mM) (days)
1 K2Au(CN)2 2 2
2 K2Au(CN)2 2 5
3 K2Pt(CN)4 1 2
4 K2Pt(NO2)4 0.02 2
5 K2Pt(NO2)4 0.02 2
respectively. Accordingly, the two data sets could not be merged
(Rmerge > 0.20).
Structure determination
Both molecular replacement (MR) and multiple isomorphous replace-
ment (MIR) methods were used to solve the structure. MR was per-
formed with the Ca backbone model of the 3a,20b-dehydrogenase
deposited within the Protein Data Bank (access code 1HSD) [24]. The
AMoRe program [47] was used to performed rotation and translation
searches. For both rotation and translation functions, the solution with
the highest correlation coefficient was the correct one. Unfortunately,
the knowledge of Ca atom positions in the unit cell did not provide us
with enough phase information to start model building and refinement.
Consequently, a derivative search was undertaken. Two heavy-atom
salts (Table 3) led to usable derivatives, for which five data sets were
collected. Analysis of Patterson difference maps, refinement of heavy
atom positions, and calculation of phases were done with the CCP4
suite of programs [42]; the statistics are presented in Table 5. The
initial MIR map was improved through solvent-flattening and histogram
matching techniques, using DM from the CCP4 suite. Several sec-
ondary structure elements could be built in the modified map, and were
confirmed by the MR solution. About 40% of the model was built
against the first map before the first cycle of refinement. X-PLOR
(version 3.1) [48] was then used for refinement, and O [49] and
FRODO [50] for model building. In this way the model was updated
until completion. Model and MIR phases were combined at the begin-
ning of refinement in order to minimize the bias from the partial model.
Two models were refined independently; one using the 1.70 Å resolu-
tion data collected at room temperature, and the other using cryogenic
data at 2.20 Å resolution. The refinement statistics are presented in
Table 2.
Accession numbers
The coordinates of both models have been deposited in the Protein
Data bank (entry codes 1FDS and 1FDT).
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